Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-06-11

AUTHORS

Niina Aaltonen, Marko Lehtonen, Katri Varonen, Gemma Arrufat Goterris, Jarmo T Laitinen

ABSTRACT

BackgroundLysophosphatidic acid (LPA) is a signalling phospholipid with multiple biological functions, mainly mediated through specific G protein-coupled receptors. Aberrant LPA signalling is being increasingly implicated in the pathology of common human diseases, such as arteriosclerosis and cancer. The lifetime of the signalling pool of LPA is controlled by the equilibrium between synthesizing and degradative enzymatic activity. In the current study, we have characterized these enzymatic pathways in rat brain by pharmacologically manipulating the enzymatic machinery required for LPA degradation.ResultsIn rat brain cryosections, the lifetime of bioactive LPA was found to be controlled by Mg2+-independent, N-ethylmaleimide-insensitive phosphatase activity, attributed to lipid phosphate phosphatases (LPPs). Pharmacological inhibition of this LPP activity amplified LPA1 receptor signalling, as revealed using functional autoradiography. Although two LPP inhibitors, sodium orthovanadate and propranolol, locally amplified receptor responses, they did not affect global brain LPA phosphatase activity (also attributed to Mg2+-independent, N-ethylmaleimide-insensitive phosphatases), as confirmed by Pi determination and by LC/MS/MS. Interestingly, the phosphate analog, aluminium fluoride (AlFx-) not only irreversibly inhibited LPP activity thereby potentiating LPA1 receptor responses, but also totally prevented LPA degradation, however this latter effect was not essential in order to observe AlFx--dependent potentiation of receptor signalling.ConclusionsWe conclude that vanadate- and propranolol-sensitive LPP activity locally guards the signalling pool of LPA whereas the majority of brain LPA phosphatase activity is attributed to LPP-like enzymatic activity which, like LPP activity, is sensitive to AlFx- but resistant to the LPP inhibitors, vanadate and propranolol. More... »

PAGES

7

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2210-12-7

DOI

http://dx.doi.org/10.1186/1471-2210-12-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017848823

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22686545


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aluminum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Vitro Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lysophospholipids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphatidate Phosphatase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propranolol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Wistar", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Lysophosphatidic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vanadates", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland", 
          "id": "http://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aaltonen", 
        "givenName": "Niina", 
        "id": "sg:person.01300600143.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300600143.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland", 
          "id": "http://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lehtonen", 
        "givenName": "Marko", 
        "id": "sg:person.01346713343.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346713343.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland", 
          "id": "http://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varonen", 
        "givenName": "Katri", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland", 
          "id": "http://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goterris", 
        "givenName": "Gemma Arrufat", 
        "id": "sg:person.0671422443.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671422443.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland", 
          "id": "http://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laitinen", 
        "givenName": "Jarmo T", 
        "id": "sg:person.014403661364.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014403661364.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc1143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016686548", 
          "https://doi.org/10.1038/nrc1143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nchembio.129", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031669425", 
          "https://doi.org/10.1038/nchembio.129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00018-006-6155-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010446751", 
          "https://doi.org/10.1007/s00018-006-6155-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-11", 
    "datePublishedReg": "2012-06-11", 
    "description": "BackgroundLysophosphatidic acid (LPA) is a signalling phospholipid with multiple biological functions, mainly mediated through specific G protein-coupled receptors. Aberrant LPA signalling is being increasingly implicated in the pathology of common human diseases, such as arteriosclerosis and cancer. The lifetime of the signalling pool of LPA is controlled by the equilibrium between synthesizing and degradative enzymatic activity. In the current study, we have characterized these enzymatic pathways in rat brain by pharmacologically manipulating the enzymatic machinery required for LPA degradation.ResultsIn rat brain cryosections, the lifetime of bioactive LPA was found to be controlled by Mg2+-independent, N-ethylmaleimide-insensitive phosphatase activity, attributed to lipid phosphate phosphatases (LPPs). Pharmacological inhibition of this LPP activity amplified LPA1 receptor signalling, as revealed using functional autoradiography. Although two LPP inhibitors, sodium orthovanadate and propranolol, locally amplified receptor responses, they did not affect global brain LPA phosphatase activity (also attributed to Mg2+-independent, N-ethylmaleimide-insensitive phosphatases), as confirmed by Pi determination and by LC/MS/MS. Interestingly, the phosphate analog, aluminium fluoride (AlFx-) not only irreversibly inhibited LPP activity thereby potentiating LPA1 receptor responses, but also totally prevented LPA degradation, however this latter effect was not essential in order to observe AlFx--dependent potentiation of receptor signalling.ConclusionsWe conclude that vanadate- and propranolol-sensitive LPP activity locally guards the signalling pool of LPA whereas the majority of brain LPA phosphatase activity is attributed to LPP-like enzymatic activity which, like LPP activity, is sensitive to AlFx- but resistant to the LPP inhibitors, vanadate and propranolol.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2210-12-7", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.4250905", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024637", 
        "issn": [
          "1471-2210"
        ], 
        "name": "BMC Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "LPA phosphatase activity", 
      "lipid phosphate phosphatases", 
      "rat brain cryosections", 
      "LPA degradation", 
      "LPP activity", 
      "phosphatase activity", 
      "LPA1 receptor", 
      "receptor responses", 
      "brain cryosections", 
      "G protein-coupled receptors", 
      "enzymatic activity", 
      "common human diseases", 
      "specific G protein-coupled receptors", 
      "protein-coupled receptors", 
      "multiple biological functions", 
      "phosphatase inhibitor", 
      "phosphate phosphatase", 
      "enzymatic machinery", 
      "biological functions", 
      "bioactive LPA", 
      "functional autoradiography", 
      "sodium orthovanadate", 
      "human diseases", 
      "rat brain", 
      "dependent potentiation", 
      "receptor signaling", 
      "LPA signaling", 
      "pharmacological inhibition", 
      "enzymatic pathways", 
      "receptors", 
      "signaling", 
      "LC/MS/MS", 
      "LPA", 
      "MS/MS", 
      "inhibitors", 
      "phosphate analogue", 
      "current study", 
      "aluminum fluoride", 
      "AlFx", 
      "cryosections", 
      "pool", 
      "degradative enzymatic activities", 
      "degradation", 
      "machinery", 
      "arteriosclerosis", 
      "latter effect", 
      "activity", 
      "propranolol", 
      "cancer", 
      "potentiation", 
      "disease", 
      "pathology", 
      "orthovanadate", 
      "pI determination", 
      "brain", 
      "response", 
      "phosphatase", 
      "pathway", 
      "autoradiography", 
      "inhibition", 
      "phospholipids", 
      "ConclusionsWe", 
      "lipids", 
      "majority", 
      "vanadate", 
      "acid", 
      "Mg2", 
      "study", 
      "function", 
      "effect", 
      "MS", 
      "analogues", 
      "synthesizing", 
      "fluoride", 
      "determination", 
      "equilibrium", 
      "order", 
      "lifetime"
    ], 
    "name": "Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation", 
    "pagination": "7", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017848823"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2210-12-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22686545"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2210-12-7", 
      "https://app.dimensions.ai/details/publication/pub.1017848823"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_560.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2210-12-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2210-12-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2210-12-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2210-12-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2210-12-7'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      121 URIs      110 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2210-12-7 schema:about N31367d38ffb54d4291cd435a5eea87e2
2 N4eae86eb412843c2a75667497f5ae428
3 N53e722c7408941a4b529f77c58919f88
4 N60fb8817b5924ca6a94d8cd4e0a3f7f7
5 N64e295835cfb4d2eb4d002b0a111c19f
6 N751d8a13862846ab94dedd5f7b12e555
7 N7da3a0b2755244e8b393a85d8e4361ff
8 N84a30a83bc1c4e158dd151f9d103b7da
9 N9323d7b8bd5b431e8da15a68ffe8cfff
10 N966d2922566d4a21afeb22e2f66c0ce2
11 Na3480e8b35f143748c9b5942265e5e90
12 Nc7ebc6b5e3ea486aa9b5b95bf645d122
13 Nceefb36784894cd6a0291b7e1a20cacc
14 Nd445c372906e4a7583c16f08a365ed88
15 Nf0001abd6d024fb29efbe59467bbe06b
16 anzsrc-for:11
17 anzsrc-for:1109
18 schema:author Ne20aaf1a355d4aceabbacae9439019c0
19 schema:citation sg:pub.10.1007/s00018-006-6155-y
20 sg:pub.10.1038/nchembio.129
21 sg:pub.10.1038/nrc1143
22 schema:datePublished 2012-06-11
23 schema:datePublishedReg 2012-06-11
24 schema:description BackgroundLysophosphatidic acid (LPA) is a signalling phospholipid with multiple biological functions, mainly mediated through specific G protein-coupled receptors. Aberrant LPA signalling is being increasingly implicated in the pathology of common human diseases, such as arteriosclerosis and cancer. The lifetime of the signalling pool of LPA is controlled by the equilibrium between synthesizing and degradative enzymatic activity. In the current study, we have characterized these enzymatic pathways in rat brain by pharmacologically manipulating the enzymatic machinery required for LPA degradation.ResultsIn rat brain cryosections, the lifetime of bioactive LPA was found to be controlled by Mg2+-independent, N-ethylmaleimide-insensitive phosphatase activity, attributed to lipid phosphate phosphatases (LPPs). Pharmacological inhibition of this LPP activity amplified LPA1 receptor signalling, as revealed using functional autoradiography. Although two LPP inhibitors, sodium orthovanadate and propranolol, locally amplified receptor responses, they did not affect global brain LPA phosphatase activity (also attributed to Mg2+-independent, N-ethylmaleimide-insensitive phosphatases), as confirmed by Pi determination and by LC/MS/MS. Interestingly, the phosphate analog, aluminium fluoride (AlFx-) not only irreversibly inhibited LPP activity thereby potentiating LPA1 receptor responses, but also totally prevented LPA degradation, however this latter effect was not essential in order to observe AlFx--dependent potentiation of receptor signalling.ConclusionsWe conclude that vanadate- and propranolol-sensitive LPP activity locally guards the signalling pool of LPA whereas the majority of brain LPA phosphatase activity is attributed to LPP-like enzymatic activity which, like LPP activity, is sensitive to AlFx- but resistant to the LPP inhibitors, vanadate and propranolol.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N03d7b060a7da4441ab3f210ef6b44d97
28 N2d35e40a472847e2922ffecaeba887b5
29 sg:journal.1024637
30 schema:keywords AlFx
31 ConclusionsWe
32 G protein-coupled receptors
33 LC/MS/MS
34 LPA
35 LPA degradation
36 LPA phosphatase activity
37 LPA signaling
38 LPA1 receptor
39 LPP activity
40 MS
41 MS/MS
42 Mg2
43 acid
44 activity
45 aluminum fluoride
46 analogues
47 arteriosclerosis
48 autoradiography
49 bioactive LPA
50 biological functions
51 brain
52 brain cryosections
53 cancer
54 common human diseases
55 cryosections
56 current study
57 degradation
58 degradative enzymatic activities
59 dependent potentiation
60 determination
61 disease
62 effect
63 enzymatic activity
64 enzymatic machinery
65 enzymatic pathways
66 equilibrium
67 fluoride
68 function
69 functional autoradiography
70 human diseases
71 inhibition
72 inhibitors
73 latter effect
74 lifetime
75 lipid phosphate phosphatases
76 lipids
77 machinery
78 majority
79 multiple biological functions
80 order
81 orthovanadate
82 pI determination
83 pathology
84 pathway
85 pharmacological inhibition
86 phosphatase
87 phosphatase activity
88 phosphatase inhibitor
89 phosphate analogue
90 phosphate phosphatase
91 phospholipids
92 pool
93 potentiation
94 propranolol
95 protein-coupled receptors
96 rat brain
97 rat brain cryosections
98 receptor responses
99 receptor signaling
100 receptors
101 response
102 signaling
103 sodium orthovanadate
104 specific G protein-coupled receptors
105 study
106 synthesizing
107 vanadate
108 schema:name Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation
109 schema:pagination 7
110 schema:productId N64ee8baa152a4122956b696397b4ef34
111 N6722b65cd9824a048d1db2b37dd17edd
112 N84e1943094d24ee890d3c811c08673bc
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017848823
114 https://doi.org/10.1186/1471-2210-12-7
115 schema:sdDatePublished 2022-11-24T20:55
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher N9db250b04ebe4f4ea5489d6027664968
118 schema:url https://doi.org/10.1186/1471-2210-12-7
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N03d7b060a7da4441ab3f210ef6b44d97 schema:issueNumber 1
123 rdf:type schema:PublicationIssue
124 N2d35e40a472847e2922ffecaeba887b5 schema:volumeNumber 12
125 rdf:type schema:PublicationVolume
126 N31367d38ffb54d4291cd435a5eea87e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Animals
128 rdf:type schema:DefinedTerm
129 N4dc2b71ef7494a408839684e8d0092ea rdf:first sg:person.0671422443.03
130 rdf:rest Nc071889068eb4aa3a1065c538d117477
131 N4eae86eb412843c2a75667497f5ae428 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Signal Transduction
133 rdf:type schema:DefinedTerm
134 N53e722c7408941a4b529f77c58919f88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aluminum Compounds
136 rdf:type schema:DefinedTerm
137 N60fb8817b5924ca6a94d8cd4e0a3f7f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Receptors, Lysophosphatidic Acid
139 rdf:type schema:DefinedTerm
140 N64e295835cfb4d2eb4d002b0a111c19f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Rats
142 rdf:type schema:DefinedTerm
143 N64ee8baa152a4122956b696397b4ef34 schema:name doi
144 schema:value 10.1186/1471-2210-12-7
145 rdf:type schema:PropertyValue
146 N6722b65cd9824a048d1db2b37dd17edd schema:name dimensions_id
147 schema:value pub.1017848823
148 rdf:type schema:PropertyValue
149 N751d8a13862846ab94dedd5f7b12e555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Rats, Wistar
151 rdf:type schema:DefinedTerm
152 N7da3a0b2755244e8b393a85d8e4361ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Vanadates
154 rdf:type schema:DefinedTerm
155 N84a30a83bc1c4e158dd151f9d103b7da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Propranolol
157 rdf:type schema:DefinedTerm
158 N84e1943094d24ee890d3c811c08673bc schema:name pubmed_id
159 schema:value 22686545
160 rdf:type schema:PropertyValue
161 N9323d7b8bd5b431e8da15a68ffe8cfff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Fluorides
163 rdf:type schema:DefinedTerm
164 N966d2922566d4a21afeb22e2f66c0ce2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 N9db250b04ebe4f4ea5489d6027664968 schema:name Springer Nature - SN SciGraph project
168 rdf:type schema:Organization
169 Na3480e8b35f143748c9b5942265e5e90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name In Vitro Techniques
171 rdf:type schema:DefinedTerm
172 Nbbbb5e89309548819a273310d5d99776 schema:affiliation grid-institutes:grid.9668.1
173 schema:familyName Varonen
174 schema:givenName Katri
175 rdf:type schema:Person
176 Nc071889068eb4aa3a1065c538d117477 rdf:first sg:person.014403661364.72
177 rdf:rest rdf:nil
178 Nc7ebc6b5e3ea486aa9b5b95bf645d122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Phosphatidate Phosphatase
180 rdf:type schema:DefinedTerm
181 Nceefb36784894cd6a0291b7e1a20cacc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Lysophospholipids
183 rdf:type schema:DefinedTerm
184 Nd078210578084d978c53a1e19ea8fc50 rdf:first sg:person.01346713343.45
185 rdf:rest Nded67f6ba80d4a9b9279567c8270f659
186 Nd445c372906e4a7583c16f08a365ed88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Enzyme Inhibitors
188 rdf:type schema:DefinedTerm
189 Nded67f6ba80d4a9b9279567c8270f659 rdf:first Nbbbb5e89309548819a273310d5d99776
190 rdf:rest N4dc2b71ef7494a408839684e8d0092ea
191 Ne20aaf1a355d4aceabbacae9439019c0 rdf:first sg:person.01300600143.07
192 rdf:rest Nd078210578084d978c53a1e19ea8fc50
193 Nf0001abd6d024fb29efbe59467bbe06b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Brain
195 rdf:type schema:DefinedTerm
196 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
197 schema:name Medical and Health Sciences
198 rdf:type schema:DefinedTerm
199 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
200 schema:name Neurosciences
201 rdf:type schema:DefinedTerm
202 sg:grant.4250905 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2210-12-7
203 rdf:type schema:MonetaryGrant
204 sg:journal.1024637 schema:issn 1471-2210
205 schema:name BMC Pharmacology
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.01300600143.07 schema:affiliation grid-institutes:grid.9668.1
209 schema:familyName Aaltonen
210 schema:givenName Niina
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300600143.07
212 rdf:type schema:Person
213 sg:person.01346713343.45 schema:affiliation grid-institutes:grid.9668.1
214 schema:familyName Lehtonen
215 schema:givenName Marko
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346713343.45
217 rdf:type schema:Person
218 sg:person.014403661364.72 schema:affiliation grid-institutes:grid.9668.1
219 schema:familyName Laitinen
220 schema:givenName Jarmo T
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014403661364.72
222 rdf:type schema:Person
223 sg:person.0671422443.03 schema:affiliation grid-institutes:grid.9668.1
224 schema:familyName Goterris
225 schema:givenName Gemma Arrufat
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671422443.03
227 rdf:type schema:Person
228 sg:pub.10.1007/s00018-006-6155-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010446751
229 https://doi.org/10.1007/s00018-006-6155-y
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/nchembio.129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031669425
232 https://doi.org/10.1038/nchembio.129
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/nrc1143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016686548
235 https://doi.org/10.1038/nrc1143
236 rdf:type schema:CreativeWork
237 grid-institutes:grid.9668.1 schema:alternateName School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
238 School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
239 schema:name School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
240 School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...